gpt-dict.com

甘胺酸 Glycine × 思覺失調症（負性症狀 NMDA 共激動劑輔助治療）

結論：主流反證據

證據呈現典型『早期小型陽性試驗被大型確證試驗推翻』之模式：1990 年代 Heresco-Levy/Javitt 等 n<30 小型 RCT 顯示 PANSS 負性症狀改善 ~30%，但 2007 年 NIMH 資助之 CONSIST 多中心 RCT（n=157, 16 週, high quality）對 SANS 為 NULL 結果，後續 2011 Singh meta-analysis 進一步顯示 glycine 與 clozapine 併用反而惡化正性症狀（SMD +0.

C 🟠 C 薄弱證據 主流反證據 ✨ low — community discussion mostly non-commercial
⚠️ 標記 🇹🇼 台灣在地警示

證據呈現典型『早期小型陽性試驗被大型確證試驗推翻』之模式：1990 年代 Heresco-Levy/Javitt 等 n<30 小型 RCT 顯示 PANSS 負性症狀改善 ~30%，但 2007 年 NIMH 資助之 CONSIST 多中心 RCT（n=157, 16 週, high quality）對 SANS 為 NULL 結果，後續 2011 Singh meta-analysis 進一步顯示 glycine 與 clozapine 併用反而惡化正性症狀（SMD +0.56），且 2023 GlyT1 抑制劑 PF-03463275 與 bitopertin Phase 3 也失敗。

L5b/c/d/e 四大權威（Mayo/Cleveland/Harvard McLean/APA 2020）無一將 glycine 列入臨床建議。

L1 Examine 給 B（n=50, 2 studies）反映其僅納入早期小樣本陽性數據，未充分權重 CONSIST null 與 Singh MA 之 clozapine 惡化訊號，方法論上偏舊。

獨立判讀為 D（反證據 / refuted by larger trial），輔以 L9 之 clozapine drug interaction safety flag。

⚖️

評分透明度

所有分數由 7 層證據引擎計算，過程公開可查
原始分數 0.47
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 主流反證據
信心度
79%
證據方向大致一致
證據層級
E3
單篇高品質統合分析

各層「支持此療效」的程度

分數越低＝該層越不支持
L11 AI 複核獨立判讀
0.30
L2 PubMed原始文獻
0.45
L3 機轉生理合理性
0.45
L1 Examine國際基準
0.50
L5 臨床機構權威立場
0.55
不支持 中性 / 混合 支持
▸查看完整決策路徑（audit trail）
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.465
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
PMID: 9892253 1999 RCT (double-blind) n = 22
結論：Glycine produced 30%+/-16% reduction in PANSS negative symptoms (p<0.001) and 30%+/-18% improvement in BPRS total (p<0.001); low baseline serum glycine predicted response (r=0.80)
政府資助 效應量：[object Object]
前往 PubMed
Placebo-controlled trial of glycine added to clozapine in schizophrenia
PMID: 10784481 2000 RCT (double-blind) n = 30
結論：No significant improvement in positive, negative or cognitive symptoms when glycine added to clozapine; authors concluded glycine-site agonists may be less effective with clozapine than with conventional antipsychotics
學術資助
前往 PubMed
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments
PMID: 17898352 2007 RCT (double-blind) n = 157
結論：NULL: no significant difference in SANS change between glycine vs placebo or D-cycloserine vs placebo; no cognitive benefit; concluded neither agent is a generally effective therapeutic option for negative symptoms or cognition
🟢 高品質 政府資助
前往 PubMed
Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia
PMID: 21936588 2011 統合分析 n = 1,253
結論：Pooled NMDA modulators: small effect on negative symptoms (SMD -0.27) and medium on total (SMD -0.40); glycine adjunct to non-clozapine showed medium effect on total (SMD -0.66) but worsened positive symptoms when added to clozapine (SMD +0.56); D-serine and sarcosine had broader benefit than glycine
效應量：[object Object]
前往 PubMed
A Pilot Randomized, Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence
PMID: 30633660 2019 RCT (double-blind) n = 20
結論：NULL: glycine showed no statistically significant advantage over placebo on heavy drinking, cravings, negative schizophrenia symptoms, or cognition; consistent with larger glycine trials
🟠 品質有限 政府資助
前往 PubMed
Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia
PMID: 37141764 2023 RCT (double-blind) n = 71
結論：Drug + cognitive training did NOT produce greater improvement in cognition vs cognitive training alone; safe and well-tolerated but failed primary efficacy; indirect glycine-site augmentation also unsuccessful
政府資助
前往 PubMed

L4a US FDA
支持
the Food and Drug Administration no longer regards glycine and its salts as generally recognized as safe for use in human food and all outstanding letters expressing sanction for such use are rescinded. 來源↗
L4b EU EFSA
反對
a cause and effect relationship has not been established 來源↗
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
胺基乙酸 Glycine：類別 (十一) 調味劑；使用食品範圍及限量：本品可於各類食品中視實際需要適量使用；使用限制：限於食品製造或加工必須時使用。 來源↗
L4e WHO
中性
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
未表態
— 本適應症無對應資料
L5b Mayo Clinic
中性
— 本適應症無對應資料
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
中性
Placebo controlled clinical trials with agents that directly or indirectly activate the glycine modulatory site consistently reduce negative symptoms and frequently improve cognition in patients with chronic schizophrenia who are receiving concurrent typical antipsychotics. 來源↗
L5e Specialty Society (condition-mapped)
未表態
— 本適應症無對應資料

PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 低度
低中高
📍立場總覽

PTT/Dcard/Mobile01/痞客邦/FB 社團查無甘胺酸用於思覺失調症（負性症狀 NMDA 共激動劑輔助）之在地使用心得；社群僅見甘胺酸（多為甘胺酸鎂）討論助眠與紓壓，屬不同用途。

💬社群實感

無共識

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

甘胺酸鎂 高吸收

代表來源 ↗
L10b · TFDA 法定身份 官方認定
🍽️一般食品

准許作為食品添加物調味劑使用

來源 ↗

  • 抗精神病藥物
  • 心理社會介入（含 CBT、家庭介入）
  • 氯氮平（治療抗性個案）
✓ PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 6 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v28 engine_version: v1.0 claim_id: CLM-COND-schizophrenia-INT-glycine-001
查看 ClaimReview 結構化資料 (JSON-LD) 
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-schizophrenia-INT-glycine-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "甘胺酸能改善思覺失調症（負性症狀 NMDA 共激動劑輔助治療）",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}